Objective To elucidate the role of transsphenoidal surgery in the treatment of pituitary microprolactinoma.Methods The clinical data of 107 prolactinoma cases treated by extra-pseudocapsular transnasal transsphenoidal...Objective To elucidate the role of transsphenoidal surgery in the treatment of pituitary microprolactinoma.Methods The clinical data of 107 prolactinoma cases treated by extra-pseudocapsular transnasal transsphenoidal surgery(ETTS)for different indications in our department since 2011 was retrospectively analyzed.Results The most common indication was the ineffectiveness of oral medication(41.1%),followed by the personal willingness of the patient(35.5%),and 20.6%of the patients were young women with clear tumor boundaries.The pseudocapsule was not observed in 63 cases(58.9%),incomplete pseudocapsule was observed in 26 cases(24.3%),and complete pseudocapsule in 18 cases(16.8%).A total of 97 patients(90.7%)obtained 1-year post-operation remission.According to the relative location of the adenoma and pituitary gland on the MRI scan,46 patients were classified into a central type,59 a lateral type,and 2 a supra-pituitary type.Two patients developed hypogonadism,one patient developed hypocortisolism,and one patient developed post-operative hypothyroidism.Two patients were administrated with hormone replacement treatment,and the treatment was stopped within one week.There was no permanent hypopituitarism.Further investigation demonstrated that the adenoma types could affect the remission rates of hyperprolactinemia and gross total resection rate in microprolactinoma.Conclusion ETTS was an effective treatment for pituitary microprolactinomas.This could be the first choice for patients who presented enclosed adenoma on the MRI and were potentially curable in a preoperative evaluation.Maximal safe removal of the adenoma by ETTS with the aim to increase the sensitivity of the drugs was also recommended for patients with invasive dopamine agonist resistant prolactinomas and patients with difficulty in childbirth.展开更多
目的对育龄期女性垂体泌乳素微腺瘤患者药物与手术治疗的疗效、不良反应及并发症进行比较。方法回顾性分析2004年1月—2006年6月确诊为垂体泌乳素微腺瘤的女性患者88例,根据治疗方法分为两组,药物组26例,手术组62例。随访各组治疗前、...目的对育龄期女性垂体泌乳素微腺瘤患者药物与手术治疗的疗效、不良反应及并发症进行比较。方法回顾性分析2004年1月—2006年6月确诊为垂体泌乳素微腺瘤的女性患者88例,根据治疗方法分为两组,药物组26例,手术组62例。随访各组治疗前、后的临床症状变化、内分泌激素水平以及生殖生育情况,并对其疗效进行评价。结果总治疗有效率为73.9%,其中药物组为69.2%,手术组为75.8%,两组问差异无统计学意义(P>0.05)。治疗后总受孕率为12/19,活胎率为10/19。药物组活胎率为7/8,明显高于手术组的3/11 (P<0.05)。药物不良反应发生率为53.8%,手术并发症发生率为24.2%。多因素回归分析显示,药物治疗后1个月泌乳素(PRL)水平是否立即恢复正常、术前PRL值/术后1 d PRL值是否≥20是预测疗效的独立危险因素。结论有生育要求的垂体泌乳素微腺瘤患者应首选药物治疗。治疗后应定期随访PRL水平以及时调整治疗方案。治疗后的1～3个月对于有生育要求的患者是关键期。展开更多
文摘Objective To elucidate the role of transsphenoidal surgery in the treatment of pituitary microprolactinoma.Methods The clinical data of 107 prolactinoma cases treated by extra-pseudocapsular transnasal transsphenoidal surgery(ETTS)for different indications in our department since 2011 was retrospectively analyzed.Results The most common indication was the ineffectiveness of oral medication(41.1%),followed by the personal willingness of the patient(35.5%),and 20.6%of the patients were young women with clear tumor boundaries.The pseudocapsule was not observed in 63 cases(58.9%),incomplete pseudocapsule was observed in 26 cases(24.3%),and complete pseudocapsule in 18 cases(16.8%).A total of 97 patients(90.7%)obtained 1-year post-operation remission.According to the relative location of the adenoma and pituitary gland on the MRI scan,46 patients were classified into a central type,59 a lateral type,and 2 a supra-pituitary type.Two patients developed hypogonadism,one patient developed hypocortisolism,and one patient developed post-operative hypothyroidism.Two patients were administrated with hormone replacement treatment,and the treatment was stopped within one week.There was no permanent hypopituitarism.Further investigation demonstrated that the adenoma types could affect the remission rates of hyperprolactinemia and gross total resection rate in microprolactinoma.Conclusion ETTS was an effective treatment for pituitary microprolactinomas.This could be the first choice for patients who presented enclosed adenoma on the MRI and were potentially curable in a preoperative evaluation.Maximal safe removal of the adenoma by ETTS with the aim to increase the sensitivity of the drugs was also recommended for patients with invasive dopamine agonist resistant prolactinomas and patients with difficulty in childbirth.
文摘目的对育龄期女性垂体泌乳素微腺瘤患者药物与手术治疗的疗效、不良反应及并发症进行比较。方法回顾性分析2004年1月—2006年6月确诊为垂体泌乳素微腺瘤的女性患者88例,根据治疗方法分为两组,药物组26例,手术组62例。随访各组治疗前、后的临床症状变化、内分泌激素水平以及生殖生育情况,并对其疗效进行评价。结果总治疗有效率为73.9%,其中药物组为69.2%,手术组为75.8%,两组问差异无统计学意义(P>0.05)。治疗后总受孕率为12/19,活胎率为10/19。药物组活胎率为7/8,明显高于手术组的3/11 (P<0.05)。药物不良反应发生率为53.8%,手术并发症发生率为24.2%。多因素回归分析显示,药物治疗后1个月泌乳素(PRL)水平是否立即恢复正常、术前PRL值/术后1 d PRL值是否≥20是预测疗效的独立危险因素。结论有生育要求的垂体泌乳素微腺瘤患者应首选药物治疗。治疗后应定期随访PRL水平以及时调整治疗方案。治疗后的1～3个月对于有生育要求的患者是关键期。
